{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T17:44:35Z","timestamp":1779126275136,"version":"3.51.4"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005189","name":"Estonian Research Competency Council","doi-asserted-by":"publisher","award":["PSG774"],"award-info":[{"award-number":["PSG774"]}],"id":[{"id":"10.13039\/501100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005189","name":"Estonian Research Competency Council","doi-asserted-by":"publisher","award":["PSG1027"],"award-info":[{"award-number":["PSG1027"]}],"id":[{"id":"10.13039\/501100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005189","name":"Estonian Research Competency Council","doi-asserted-by":"publisher","award":["PRG2040"],"award-info":[{"award-number":["PRG2040"]}],"id":[{"id":"10.13039\/501100005189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-43459-y","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T10:45:25Z","timestamp":1773398725000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Exploring the hereditary genetic mutational landscape of breast and ovarian cancer in Estonia"],"prefix":"10.1038","volume":"16","author":[{"given":"Mikk","family":"Tooming","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kadri","family":"Toome","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kadri","family":"Rekker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Roht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piret","family":"Laidre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Fjodorova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanno","family":"Roomere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00dclle","family":"Murumets","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ustina","family":"\u0160amarina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sander","family":"Pajusalu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riina","family":"\u017dordania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristi","family":"Tael","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eve","family":"Vaidla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elvira","family":"Kurvinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neeme","family":"T\u00f5nisson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihkel","family":"Ilisson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peeter","family":"Padrik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaak","family":"Lehtsaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riina","family":"K\u00fctner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elen","family":"Vettus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Vahar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilleriin","family":"Peets","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrin","family":"\u00d5unap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiina","family":"Kahre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"43459_CR1","unstructured":"WHO. WHO, Cancer today. https:\/\/gco.iarc.who.int\/today\/ (2026)."},{"key":"43459_CR2","unstructured":"HSHRD. PK10: Pahaloomuliste kasvajate esmasjuhud paikme, soo ja vanuser\u00fchma j\u00e4rgi. Tervisestatistika ja terviseuuringute andmebaas http:\/\/statistika.tai.ee\/pxweb\/et\/Andmebaas\/Andmebaas__02Haigestumus__04PahaloomulisedKasvajad\/PK10.px\/ (2026)."},{"key":"43459_CR3","unstructured":"Casaubon, J. T., Kashyap, S. & Regan, J.-P. BRCA1 and BRCA2 Mutations. In: StatPearls (StatPearls Publishing, Treasure Island (FL), 2024)."},{"key":"43459_CR4","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s12282-020-01148-2","volume":"28","author":"R Yoshida","year":"2021","unstructured":"Yoshida, R. Hereditary breast and ovarian cancer (HBOC): Review of its molecular characteristics, screening, treatment, and prognosis. Breast Cancer 28, 1167\u20131180 (2021).","journal-title":"Breast Cancer"},{"key":"43459_CR5","unstructured":"Daly, M. B. et al. NCCN Guidelines\u00ae Insights: Genetic\/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2026. J. Nation. Comprehens. Cancer Network: JNCCN https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_bopp.pdf (2025)."},{"key":"43459_CR6","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41431-023-01507-5","volume":"32","author":"T McDevitt","year":"2024","unstructured":"McDevitt, T. et al. EMQN best practice guidelines for genetic testing in hereditary breast and ovarian cancer. Eur. J. Hum. Genet. 32, 479\u2013488 (2024).","journal-title":"Eur. J. Hum. Genet."},{"key":"43459_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15082357","volume":"15","author":"SSY Wang","year":"2023","unstructured":"Wang, S. S. Y., Jie, Y. E., Cheng, S. W., Ling, G. L. & Ming, H. V. Y. PARP inhibitors in breast and ovarian cancer. Cancers (Basel) 15, 2357 (2023).","journal-title":"Cancers (Basel)"},{"key":"43459_CR8","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s11523-021-00796-4","volume":"16","author":"L Cortesi","year":"2021","unstructured":"Cortesi, L., Rugo, H. S. & Jackisch, C. An overview of PARP inhibitors for the treatment of breast cancer. Target. Oncol. 16, 255\u2013282 (2021).","journal-title":"Target. Oncol."},{"key":"43459_CR9","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s11523-023-00970-w","volume":"18","author":"DM O\u2019Malley","year":"2023","unstructured":"O\u2019Malley, D. M., Krivak, T. C., Kabil, N., Munley, J. & Moore, K. N. PARP inhibitors in ovarian cancer: A review. Target. Oncol. 18, 471\u2013503 (2023).","journal-title":"Target. Oncol."},{"key":"43459_CR10","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/14366","volume":"23","author":"A Metspalu","year":"1999","unstructured":"Metspalu, A. et al. Universal and flexible DNA microarray approach: Arrayed primer extension. Nat. Genet. 23, 62\u201363 (1999).","journal-title":"Nat. Genet."},{"key":"43459_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/1897-4287-8-4","volume":"8","author":"K Tamboom","year":"2010","unstructured":"Tamboom, K. et al. BRCA1 mutations in women with familial or early-onset breast cancer and BRCA2 mutations in familial cancer in Estonia. Hered. Cancer Clin. Pract. 8, 4 (2010).","journal-title":"Hered. Cancer Clin. Pract."},{"key":"43459_CR12","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754\u20131760 (2009).","journal-title":"Bioinformatics"},{"key":"43459_CR13","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1101\/gr.107524.110","volume":"20","author":"A McKenna","year":"2010","unstructured":"McKenna, A. et al. The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297\u20131303 (2010).","journal-title":"Genome Res."},{"key":"43459_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2012.00035","author":"D Ruden","year":"2012","unstructured":"Ruden, D. et al. Using Drosophila melanogaster as a model for genotoxic chemical mutational studies with a new program, SnpSift. Front. Genet. https:\/\/doi.org\/10.3389\/fgene.2012.00035 (2012).","journal-title":"Front. Genet."},{"key":"43459_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkq603","volume":"38","author":"K Wang","year":"2010","unstructured":"Wang, K., Li, M. & Hakonarson, H. ANNOVAR: Functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164 (2010).","journal-title":"Nucleic Acids Res."},{"key":"43459_CR16","unstructured":"RefSeq: NCBI Reference Sequence Database. https:\/\/www.ncbi.nlm.nih.gov\/refseq\/."},{"key":"43459_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1007752","volume":"14","author":"MS Cline","year":"2018","unstructured":"Cline, M. S. et al. BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2. PLoS Genet. 14, e1007752 (2018).","journal-title":"PLoS Genet."},{"key":"43459_CR18","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1093\/nar\/29.1.308","volume":"29","author":"ST Sherry","year":"2001","unstructured":"Sherry, S. T. dbSNP: The NCBI database of genetic variation. Nucleic Acids Res. 29, 308\u2013311 (2001).","journal-title":"Nucleic Acids Res."},{"key":"43459_CR19","doi-asserted-by":"publisher","first-page":"D840","DOI":"10.1093\/nar\/gkw971","volume":"45","author":"KJ Karczewski","year":"2017","unstructured":"Karczewski, K. J. et al. The ExAC browser: Displaying reference data information from over 60 000 exomes. Nucleic Acids Res. 45, D840\u2013D845 (2017).","journal-title":"Nucleic Acids Res."},{"key":"43459_CR20","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41586-023-06045-0","volume":"625","author":"S Chen","year":"2024","unstructured":"Chen, S. et al. A genomic mutational constraint map using variation in 76,156 human genomes. Nature 625, 92\u2013100 (2024).","journal-title":"Nature"},{"key":"43459_CR21","doi-asserted-by":"publisher","first-page":"D980","DOI":"10.1093\/nar\/gkt1113","volume":"42","author":"MJ Landrum","year":"2014","unstructured":"Landrum, M. J. et al. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res 42, D980-985 (2014).","journal-title":"Nucleic Acids Res"},{"key":"43459_CR22","doi-asserted-by":"publisher","first-page":"D793","DOI":"10.1093\/nar\/gkn665","volume":"37","author":"J Amberger","year":"2009","unstructured":"Amberger, J., Bocchini, C. A., Scott, A. F. & Hamosh, A. McKusick\u2019s Online Mendelian Inheritance in Man (OMIM\u00ae). Nucleic Acids Res. 37, D793\u2013D796 (2009).","journal-title":"Nucleic Acids Res."},{"key":"43459_CR23","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1101\/gr.138115.112","volume":"22","author":"N Krumm","year":"2012","unstructured":"Krumm, N. et al. Copy number variation detection and genotyping from exome sequence data. Genome Res. 22, 1525\u20131532 (2012).","journal-title":"Genome Res."},{"key":"43459_CR24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/978-1-0716-2293-3_6","volume":"2493","author":"A Fowler","year":"2022","unstructured":"Fowler, A. DECoN: A detection and visualization tool for exonic copy number variants. Methods. Mol. Biol. 2493, 77\u201388 (2022).","journal-title":"Methods. Mol. Biol."},{"key":"43459_CR25","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405\u2013423 (2015).","journal-title":"Genet. Med."},{"key":"43459_CR26","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1002\/humu.22981","volume":"37","author":"JT den Dunnen","year":"2016","unstructured":"den Dunnen, J. T. et al. HGVS recommendations for the description of sequence variants: 2016 Update. Hum. Mutat. 37, 564\u2013569 (2016).","journal-title":"Hum. Mutat."},{"key":"43459_CR27","doi-asserted-by":"crossref","unstructured":"Evans, D. G. R. et al. The Angelina Jolie effect: How high celebrity profile can have a major impact on provision of cancer related services. Breast Cancer Res. 16\u00a0442. (2014).","DOI":"10.1186\/s13058-014-0442-6"},{"issue":"1","key":"43459_CR28","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13073-015-0128-4","volume":"7","author":"I Slade","year":"2015","unstructured":"Slade, I. et al. Development of cancer genetic services in the UK: A national consultation. Genome Med. 718. (2015).","journal-title":"Genome Med."},{"key":"43459_CR29","doi-asserted-by":"publisher","first-page":"436","DOI":"10.7861\/clinmedicine.14-4-436","volume":"14","author":"N Rahman","year":"2014","unstructured":"Rahman, N. Mainstreaming genetic testing of cancer predisposition genes. Clin Med (Lond) 14, 436\u2013439 (2014).","journal-title":"Clin Med (Lond)"},{"key":"43459_CR30","doi-asserted-by":"publisher","first-page":"e414","DOI":"10.1111\/ajco.13741","volume":"18","author":"E Ip","year":"2022","unstructured":"Ip, E. et al. Evaluation of a mainstream genetic testing program for women with ovarian or breast cancer. Asia Pac. J. Clin. Oncol. 18, e414\u2013e419 (2022).","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"43459_CR31","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ygyno.2017.01.030","volume":"145","author":"M Kentwell","year":"2017","unstructured":"Kentwell, M. et al. Mainstreaming cancer genetics: A model integrating germline BRCA testing into routine ovarian cancer clinics. Gynecol. Oncol. 145, 130\u2013136 (2017).","journal-title":"Gynecol. Oncol."},{"key":"43459_CR32","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/cncr.26284","volume":"118","author":"JK Litton","year":"2012","unstructured":"Litton, J. K. et al. Earlier Age of Onset of BRCA Mutation-Related Cancers in Subsequent Generations. Cancer 118, 321\u2013325 (2012).","journal-title":"Cancer"},{"key":"43459_CR33","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker, K. B. et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA 317, 2402\u20132416 (2017).","journal-title":"JAMA"},{"key":"43459_CR34","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1001\/jamaoncol.2015.5495","volume":"2","author":"BM Norquist","year":"2016","unstructured":"Norquist, B. M. et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol. 2, 482\u2013490 (2016).","journal-title":"JAMA Oncol."},{"key":"43459_CR35","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.jgo.2020.01.001","volume":"11","author":"Y Chavarri-Guerra","year":"2020","unstructured":"Chavarri-Guerra, Y., Slavin, T. P., Longoria-Lozano, O. & Weitzel, J. N. Genetic cancer predisposition syndromes among older adults. J. Geriatr. Oncol. 11, 1054\u20131060 (2020).","journal-title":"J. Geriatr. Oncol."},{"key":"43459_CR36","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.31577","volume":"8","author":"JE Mortimer","year":"2025","unstructured":"Mortimer, J. E. et al. Prevalence of BRCA1 and BRCA2 variants in an unselected population of women with breast cancer. JAMA Netw Open 8, e2531577 (2025).","journal-title":"JAMA Netw Open"},{"key":"43459_CR37","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/s41431-023-01380-2","volume":"31","author":"J Henkel","year":"2023","unstructured":"Henkel, J. et al. Diagnostic yield and clinical relevance of expanded germline genetic testing for nearly 7000 suspected HBOC patients. Eur. J. Hum. Genet. 31, 925\u2013930 (2023).","journal-title":"Eur. J. Hum. Genet."},{"key":"43459_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11229-y","volume":"23","author":"A \u00d6fverholm","year":"2023","unstructured":"\u00d6fverholm, A. et al. Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer. BMC Cancer 23, 738 (2023).","journal-title":"BMC Cancer"},{"key":"43459_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2021.104350","volume":"64","author":"DH Marmolejo","year":"2021","unstructured":"Marmolejo, D. H. et al. Overview of hereditary breast and ovarian cancer (HBOC) guidelines across Europe. Eur. J. Med. Genet. 64, 104350 (2021).","journal-title":"Eur. J. Med. Genet."},{"key":"43459_CR40","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/humu.23406","volume":"39","author":"TR Rebbeck","year":"2018","unstructured":"Rebbeck, T. R. et al. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat 39, 593\u2013620 (2018).","journal-title":"Hum Mutat"},{"key":"43459_CR41","unstructured":"JKL-165_Pariliku_rinna-_ja_munasarjavahi_kasitlusjuhend_04.pdf."},{"key":"43459_CR42","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s13167-010-0037-y","volume":"1","author":"R Janavi\u010dius","year":"2010","unstructured":"Janavi\u010dius, R. Founder BRCA1\/2 mutations in the Europe: Implications for hereditary breast-ovarian cancer prevention and control. EPMA J. 1, 397\u2013412 (2010).","journal-title":"EPMA J."},{"key":"43459_CR43","doi-asserted-by":"publisher","DOI":"10.5936\/csbj.201204005","volume":"1","author":"SL Clark","year":"2012","unstructured":"Clark, S. L., Rodriguez, A. M., Snyder, R. R., Hankins, G. D. V. & Boehning, D. Structure-function of the tumor suppressor BRCA1. Comput. Struct. Biotechnol. J. 1, e201204005 (2012).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"43459_CR44","doi-asserted-by":"publisher","first-page":"5256","DOI":"10.1093\/nar\/gkw242","volume":"44","author":"G Chatterjee","year":"2016","unstructured":"Chatterjee, G., Jimenez-Sainz, J., Presti, T., Nguyen, T. & Jensen, R. B. Distinct binding of BRCA2 BRC repeats to RAD51 generates differential DNA damage sensitivity. Nucleic Acids Res. 44, 5256\u20135270 (2016).","journal-title":"Nucleic Acids Res."},{"key":"43459_CR45","doi-asserted-by":"publisher","first-page":"e21350","DOI":"10.7554\/eLife.21350","volume":"6","author":"RW Anantha","year":"2017","unstructured":"Anantha, R. W. et al. Functional and mutational landscapes of BRCA1 for homology-directed repair and therapy resistance. Elife 6, e21350 (2017).","journal-title":"Elife"},{"key":"43459_CR46","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41431-020-00760-2","volume":"29","author":"L Leitsalu","year":"2021","unstructured":"Leitsalu, L. et al. Genotype-first approach to the detection of hereditary breast and ovarian cancer risk, and effects of risk disclosure to biobank participants. Eur. J. Hum. Genet. 29, 471\u2013481 (2021).","journal-title":"Eur. J. Hum. Genet."},{"key":"43459_CR47","doi-asserted-by":"publisher","first-page":"881100","DOI":"10.3389\/fgene.2022.881100","volume":"13","author":"H J\u00fcrgens","year":"2022","unstructured":"J\u00fcrgens, H. et al. Precise, Genotype-First Breast Cancer Prevention: Experience With Transferring Monogenic Findings From a Population Biobank to the Clinical Setting. Front Genet 13, 881100 (2022).","journal-title":"Front Genet"},{"key":"43459_CR48","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/ejhg.2010.203","volume":"19","author":"N Hamel","year":"2011","unstructured":"Hamel, N. et al. On the origin and diffusion of BRCA1 c.5266dupC (5382insC) in European populations. Eur. J. Hum. Genet. 19, 300\u2013306 (2011).","journal-title":"Eur. J. Hum. Genet."},{"key":"43459_CR49","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13053-021-00168-z","volume":"19","author":"P Loza","year":"2021","unstructured":"Loza, P. et al. A novel frequent BRCA1 recurrent variant c.5117G > A (p.Gly1206Glu) identified after 20\u2009years of BRCA1\/2 research in the Baltic region: Cohort study and literature review. Hered. Cancer Clin. Pract. 19, 11 (2021).","journal-title":"Hered. Cancer Clin. Pract."},{"key":"43459_CR50","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.cancergen.2014.05.002","volume":"207","author":"R Janavi\u010dius","year":"2014","unstructured":"Janavi\u010dius, R., Rudaitis, V., Mickys, U., Elsakov, P. & Gri\u0161kevi\u010dius, L. Comprehensive BRCA1 and BRCA2 mutational profile in Lithuania. Cancer Genet. 207, 195\u2013205 (2014).","journal-title":"Cancer Genet."},{"key":"43459_CR51","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1086\/302922","volume":"66","author":"B G\u00f3rski","year":"2000","unstructured":"G\u00f3rski, B. et al. Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. Am. J. Hum. Genet. 66, 1963\u20131968 (2000).","journal-title":"Am. J. Hum. Genet."},{"key":"43459_CR52","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1002\/ijc.20162","volume":"110","author":"B G\u00f3rski","year":"2004","unstructured":"G\u00f3rski, B. et al. A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int. J. Cancer. 110, 683\u2013686 (2004).","journal-title":"Int. J. Cancer."},{"key":"43459_CR53","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1002\/cncr.32083","volume":"125","author":"JN Weitzel","year":"2019","unstructured":"Weitzel, J. N. et al. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer. Cancer 125, 2829\u20132836 (2019).","journal-title":"Cancer"},{"key":"43459_CR54","doi-asserted-by":"publisher","first-page":"13003","DOI":"10.3390\/cimb46110775","volume":"46","author":"V Rocca","year":"2024","unstructured":"Rocca, V. et al. Germline variant spectrum in Southern Italian high-risk hereditary breast cancer patients: Insights from multi-gene panel testing. Curr. Issues Mol. Biol. 46, 13003\u201313020 (2024).","journal-title":"Curr. Issues Mol. Biol."},{"key":"43459_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2024.101101","volume":"26","author":"S Hini\u0107","year":"2024","unstructured":"Hini\u0107, S. et al. The heterogeneous cancer phenotype of individuals with biallelic germline pathogenic variants in CHEK2. Genet. Med. 26, 101101 (2024).","journal-title":"Genet. Med."},{"key":"43459_CR56","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13048-020-00654-3","volume":"13","author":"M Suszynska","year":"2020","unstructured":"Suszynska, M., Ratajska, M. & Kozlowski, P. BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: Mutation prevalence and precise risk estimates based on a pooled analysis of ~30,000 cases. J. Ovarian Res. 13, 50 (2020).","journal-title":"J. Ovarian Res."},{"key":"43459_CR57","doi-asserted-by":"publisher","DOI":"10.1200\/PO-24-00902","author":"AT Nelson","year":"2025","unstructured":"Nelson, A. T. et al. Prognostic significance of germline DICER1 pathogenic or likely pathogenic variants in outcomes of Ovarian Sertoli-Leydig Cell Tumor. JCO Precis. Oncol. https:\/\/doi.org\/10.1200\/PO-24-00902 (2025).","journal-title":"JCO Precis. Oncol."},{"key":"43459_CR58","doi-asserted-by":"publisher","first-page":"4373","DOI":"10.1200\/JCO.2010.33.6446","volume":"29","author":"E Lee","year":"2011","unstructured":"Lee, E. et al. Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: Results from a population-based study of young women. J. Clin. Oncol. 29, 4373\u20134380 (2011).","journal-title":"J. Clin. Oncol."},{"key":"43459_CR59","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/PAP.0000000000000243","volume":"26","author":"Y Hatano","year":"2019","unstructured":"Hatano, Y. et al. A comprehensive review of ovarian serous carcinoma. Adv. Anat. Pathol. 26, 329\u2013339 (2019).","journal-title":"Adv. Anat. Pathol."},{"key":"43459_CR60","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.cancergen.2012.01.008","volume":"205","author":"J Liu","year":"2012","unstructured":"Liu, J. et al. Clinical characteristics and outcomes of BRCA-associated ovarian cancer: Genotype and survival. Cancer Genet. 205, 34\u201341 (2012).","journal-title":"Cancer Genet."},{"key":"43459_CR61","doi-asserted-by":"publisher","unstructured":"Fentiman, I. Genetics of male breast cancer. In Male Breast Cancer (ed. Fentiman, I.) 43\u201360\u00a0https:\/\/doi.org\/10.1007\/978-3-031-89929-4_3 (Springer Nature Switzerland, 2025).","DOI":"10.1007\/978-3-031-89929-4_3"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43459-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43459-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43459-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T01:02:38Z","timestamp":1776992558000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43459-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["43459"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-43459-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"14 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All procedures involving human participants were conducted in accordance with institutional guidelines and the Declaration of Helsinki. Written informed consent for genetic testing and the use of anonymized clinical data for research purposes was obtained from all participants and\/or their legal guardians. The manuscript does not include any images or information that could identify individual participants; therefore, specific consent for publication of identifying information was not required. The study was approved by the Research Ethics Committee of the University of Tartu (332\/T 2, 21.12.2020; 341\/M 2, 17.02.2021; 359\/M 9, 21.02.2022; 384\/M 14, 20.11.2023; 389\/M 1, 15.04.2024).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"13373"}}